Figures computed from official regulatory filings — .
Analysttarget 3 USD (+599900%) · consensus 4/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 0% · institutions 0.15% · short 8.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Kuvatris Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
2 buys50 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Weisman Howard J. | Other | $2K | SEC | ||
| Other |
| $2.3K |
| SEC |
| CASAMENTO CHARLES Jtrack record | Other | $684.5 | SEC |
| Coelho John F | Other | $142.8 | SEC |
| LaRochelle Karen | Other | $416.8 | SEC |
| Rome Zachary | Other | $3.4K | SEC |
| Hough David W. | Other | $1K | SEC |
| Hough David W. | Other | $192.1 | SEC |
| Sheldon Stephen | Other | $160.4 | SEC |
| Rome Zachary | Sell | $389.3 | SEC |
| Coelho John F | Sell | $13 | SEC |
| CASAMENTO CHARLES Jtrack record | Other | $73.7 | SEC |
| Weisman Howard J. | Sell | $174.8 | SEC |
| LaRochelle Karen | Sell | $37.4 | SEC |
| Coelho John F | Sell | $12.4 | SEC |
| Derby Michael | Sell | $190.6 | SEC |
| Rome Zachary | Sell | $369.8 | SEC |
| LaRochelle Karen | Sell | $36.1 | SEC |
| Weisman Howard J. | Sell | $166.9 | SEC |
| Sheldon Stephen | Other | $1.7K | SEC |
| Weisman Howard J. | Sell | $1.5K | SEC |
| Derby Michael | Sell | $1.7K | SEC |
| Coelho John F | Sell | $108.3 | SEC |
| Rome Zachary | Sell | $2.9K | SEC |
| LaRochelle Karen | Sell | $319 | SEC |